Literature DB >> 18558169

Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial.

Shawn D St Peter1, Kuojen Tsao, Troy L Spilde, George W Holcomb, Susan W Sharp, J Patrick Murphy, Charles L Snyder, Ronald J Sharp, Walter S Andrews, Daniel J Ostlie.   

Abstract

INTRODUCTION: Appendicitis is the most common emergency condition in children. Historically, a 3-drug regimen consisting of ampicillin, gentamicin, and clindamycin (AGC) has been used postoperatively for perforated appendicitis. A retrospective review at our institution has found single day dosing of ceftriaxone and metronidazole (CM) to be a more simple and cost-effective antibiotic strategy. Therefore, we performed a prospective, randomized trial to compare efficacy and cost-effectiveness of these 2 regimens.
METHODS: After internal review board approval (IRB no. 04 12-149), children found to have perforated appendicitis at appendectomy were randomized to either once daily dosing of CM (2 total doses per day) or standard dosing of AGC (11 total doses per day). Perforation was defined as an identifiable hole in the appendix. The operative approach (laparoscopic), length of antibiotic use, and criteria for discharge were standardized for the groups. Based on our retrospective analysis using length of postoperative hospitalization as a primary end point, a sample size of 100 patients was calculated for an alpha of .5 and a power of 0.82.
RESULTS: One hundred patients underwent laparoscopic appendectomy for perforated appendicitis. On presentation, there were no differences in sex distribution, days of symptoms, temperature, or leukocyte count. There was no difference in abscess rate or wound infections between groups. The CM group resulted in significantly less antibiotic charges then the AGC group.
CONCLUSIONS: Once daily dosing with the 2-drug regimen (CM) offers a more efficient, cost-effective antibiotic management in children with perforated appendicitis without compromising infection control when compared to a traditional 3-drug regimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558169      PMCID: PMC3082440          DOI: 10.1016/j.jpedsurg.2008.02.018

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  23 in total

1.  Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.

Authors:  A Pession; A Prete; G Paolucci
Journal:  Chemotherapy       Date:  1997 Sep-Oct       Impact factor: 2.544

2.  An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.

Authors:  E T Smyth; J G Barr; C A O'Neill; G M Hogg
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

3.  Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.

Authors:  R Charnas; A R Lüthi; W Ruch
Journal:  Pediatr Infect Dis J       Date:  1997-04       Impact factor: 2.129

4.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

5.  A cost-effectiveness evaluation of 3 antimicrobial regimens for the prevention of infective complications after abdominal surgery.

Authors:  G Anderson; C Boldiston; S Woods; P O'Brien
Journal:  Arch Surg       Date:  1996-07

6.  A prospective, randomised comparison of single- vs. multiple-dose antibiotic prophylaxis in penetrating trauma.

Authors:  A Schmidt-Matthiesen; H Röding; J Windolf; D Sommerfeldt; C Gutt; A Pannike; A Encke
Journal:  Chemotherapy       Date:  1999 Sep-Oct       Impact factor: 2.544

7.  Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.

Authors:  E Castagnola; E Lanino; R Giacchino; C Viscoli; G Dini
Journal:  J Chemother       Date:  1999-02       Impact factor: 1.714

8.  A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections.

Authors:  G J de Klerk; J H van Steijn; S Lobatto; C A Jaspers; W C van Veldhuizen; C A Hensing; M C Bunnik; W H Geraedts; A S Dofferhof; J Van Den Berg; J H Melis; A I Hoepelman
Journal:  Int J Antimicrob Agents       Date:  1999-07       Impact factor: 5.283

9.  A simple and more cost-effective antibiotic regimen for perforated appendicitis.

Authors:  Shawn D St Peter; Danny C Little; Casey M Calkins; J Patrick Murphy; Walter S Andrews; George W Holcomb; Ronald J Sharp; Charles L Snyder; Daniel J Ostlie
Journal:  J Pediatr Surg       Date:  2006-05       Impact factor: 2.545

10.  Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.

Authors: 
Journal:  Eur J Surg Suppl       Date:  1994
View more
  29 in total

Review 1.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

2.  Reduced use of computed tomography in patients treated with interval appendectomy after implementing a protocol from a prospective, randomized trial.

Authors:  E Marty Knott; Priscilla Thomas; Nicole E Sharp; Alessandra C Gasior; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2013-07-27       Impact factor: 1.827

3.  Home intravenous versus oral antibiotics following appendectomy for perforated appendicitis in children: a randomized controlled trial.

Authors:  Michael R Arnold; Blair A Wormer; Angela M Kao; David A Klima; Paul D Colavita; Graham H Cosper; Brant Todd Heniford; Andrew M Schulman
Journal:  Pediatr Surg Int       Date:  2018-09-14       Impact factor: 1.827

4.  Efficacy of oral antibiotics in children with post-operative abscess from perforated appendicitis.

Authors:  Joseph A Sujka; Katrina L Weaver; Justin A Sobrino; Ashwini Poola; Katherine W Gonzalez; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2018-12-03       Impact factor: 1.827

5.  Successful nonoperative management of uncomplicated appendicitis: predictors and outcomes.

Authors:  Tyler J Loftus; Scott C Brakenridge; Chasen A Croft; R Stephen Smith; Philip A Efron; Frederick A Moore; Alicia M Mohr; Janeen R Jordan
Journal:  J Surg Res       Date:  2017-11-13       Impact factor: 2.192

6.  Once Daily Dosing of Ceftriaxone and Metronidazole in Children With Perforated Appendicitis.

Authors:  Ji Yeon Lee; Saudia Ally; Brian Kelly; David Kays; Lisa Thames
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

7.  Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis.

Authors:  Hanna Alemayehu; Amita A Desai; Priscilla Thomas; Susan W Sharp; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2014-01-28       Impact factor: 1.827

8.  Prolonged antibiotic treatment does not prevent intra-abdominal abscesses in perforated appendicitis.

Authors:  K van Wijck; J R de Jong; L W E van Heurn; D C van der Zee
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

9.  Evidence-based adjustment of antibiotic in pediatric complicated appendicitis in the era of antibiotic resistance.

Authors:  Kin Wai Edwin Chan; Kim Hung Lee; Jennifer Wai Cheung Mou; Sing Tak Cheung; Jennifer Dart Yin Sihoe; Yuk Him Tam
Journal:  Pediatr Surg Int       Date:  2010-02       Impact factor: 1.827

10.  To drain or not to drain: an analysis of abscess drains in the treatment of appendicitis with abscess.

Authors:  Alessandra C Gasior; E Marty Knott; Daniel J Ostlie; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2013-01-24       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.